Titration of serum CEA, p53 antibodies and CEA-IgM complexes in 142 patients with colorectal cancer and 150 healthy blood donors

Annals of Cancer Research and Therapy

Volumn 19, Issue 1, 2011, Pages 15-19

  Kojima, Taiki ^a   Matsui, Takanori ^b   Fujimitsu, Yasunobu ^b   Kojima, Hiroshi ^b   Uno, Hayato ^c   Hiramatsu, Kazuhiro ^d   Inagaki, Hitoshi ^e   Oda, Kazushige ^f   Ishiyama, Akiharu ^g   Iwata, Naoki ^h   Nakayama, Goro ^h   Kodera, Yasuhiro ^h  

^a Kojima Family Clinic   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c Uno Hospital   (Japan)

^d TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^e Yokoyama Hospital for Gastroenterological Diseases   (Japan)

^f Gamagori Municipal Hospital   (Japan)

^g Okazaki City Hospital   (Japan)

^h NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cea; Cea igm complexes; Colorectal cancer; P53 antibodies; Tumor marker

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN IMMUNOGLOBULIN M COMPLEX; IMMUNOGLOBULIN M; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FALSE POSITIVE RESULT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; SENSITIVITY AND SPECIFICITY;

EID: 79955932138     PISSN: 13446835     EISSN: None     Source Type: Journal    
DOI: 10.4993/acrt.19.15     Document Type: Article

References (21)

1. Jemal, A., Tiwari, R.C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E.J., Thun, M.J. (2004) Cancer statistics 54:8-29.
2. American Cancer Society (2000) Cancer facts and Figures. American Cancer Society, Washington DC, pp 1-39.
3. Thomas, F.I., David, F.R., Steven, H.I., Barry, A.T., Michael, E.R. (2004) Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average risk population. N Engl J Med 351:2704-2714.
4. Lieberman, D.A., Weiss, D.G. (2001) One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 345:355-360.
5. Fletcher, R.H. (1986) Carcinoembryonic antigen Ann Intern Med 104:66-73.
6. Shimada, H., Ochiai, T., Nomura, F.; Japan p53 Antibody Research Group (2003) Titration of serum p53 antibodies in 1085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer 97:682-689.
7. Levine, A., Momand, J., Finlay, C. (1991) The p53 tumor suppressor gene. Nature 351:453-455.
8. Castaldi, F., Marino, M., Belluco, C., De Marchi, F., Mammano, E., Nitti, D., Lise, M., Fassina, G. (2005) Detection of circulating CEA-IgM complexes in early stage colorectal cancer. Int J Biol Markers 20: 204-208.
9. Kojima, T., Yoshikawa, K., Matsui, T., Kodera, Y., Kojima, H. (2009) Titration of serum CEA, p53 antibodies and CEA-IgM complexes in patients with colorectal cancer. Mol Med Reports 2: 477-480.
10. Peter Dalgaad (2002) Introductory statistics with R. Springer-Verlag, New York.
11. Saif, M.W., Zalonis Syrigos, K. (2007) The clinical significance of autoantibodies in gastrointestinal malignancies: an overview. Expert Opin Ther 7: 493-507.
12. Vollmers, H.P., Brandlein, S. (2007) Natural antibodies and cancer. J Autoimmunity 29: 295-302.
13. Yahui, S., Jing, S., Huachong, M., Jiafu, J., Hong, M., Longhua, M., Weihua, Z., Ling, M., Zhenfu, L., Jian, W., Genglin, J., Jianzhi, Z. et al (2007) Diagnosis of gastric cancer using decision tree classification of mass spectra data. Cancer Sci 98:37-43.
14. Kojima, T., Yoshikawa, K., Matsui, T., Kodera, Y., Kojima, H. (2009) Detection of elevated proteins in peritoneal dissemination of gastric cancer by analyzing mass spectra data of serum proteins. J Surg Res 155: 13-17.
15. Wilson, S., Taskila, T., Hobbs, R. et al (2009) Establishing the added benefit of measuring MMP9 in FOB positivepatients as a part of the Wolverhampton colorectal cancer screening programme. BMC Cancer 9: 36-39.
16. Herszenyli, L., Farinati, F., Tulassay, Z. et al (2008) Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. BMC Cancer 8:194-205.
17. Tagi, T., Matsui, T., Kikuchi, K., Otsuji, E. et al (2010) Dermokine as a novel biomarker for early-stage colorectal cancer. J Gastroenterol 45: 1201-1211.
18. Cunningham, D., Atkin, W., Lenz, H.J., Lynch, H.T., Minsky, B., Nordllinger, B., Starling, N. (2010) Colorectal cancer. Lancet 375:1030-47.
19. Gorelik, E., Landsittel, D.P., Marrangoni, A.M., Mondugno, F., Velikokhatnaya, L., Winans, M.T., Bigbee, W.L., Herberman, R.B., Lokshin, A.E. (2005) Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 14:981-987.
20. Beneduce, L., Prayer-Galetti, T., Giustinian, A.M., Gallotta, A., Betto, G., Pagano Fassina, G. (2007) Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patients. Cancer Detect Prev. 31:402-407.
21. Beneduce, L., Castaldi, F., Marianno, M., Quarta, S., Ruvoletto, M., Fassina, G. et al (2005) Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma. Cancer 103: 2558-65.